Royalty Term. Vertex will pay royalties to Company under this Section 6.3 on a Product-by-Product and a country-by-country basis during the Royalty Term for the applicable Product in the applicable country. Upon the expiration of the Royalty Term for a given Product in a given country, the license granted to Vertex under Section 5.1.1 will become fully-paid, perpetual and irrevocable with respect to such Product in such country.
Appears in 3 contracts
Sources: Sublicense Agreement (Entrada Therapeutics, Inc.), Sublicense Agreement (Entrada Therapeutics, Inc.), Sublicense Agreement (Entrada Therapeutics, Inc.)
Royalty Term. Vertex will pay royalties to Company under this Section 6.3 5.4 on a Product-by-Product and a country-by-country basis during the Royalty Term for the applicable Product in the applicable country. Upon the expiration of the Royalty Term for a given Product in a given country, the license granted to Vertex under Section 5.1.1 4.1.1 will become fully-paid, perpetual and irrevocable with respect to such Product in such country.
Appears in 3 contracts
Sources: Strategic Collaboration and License Agreement (Entrada Therapeutics, Inc.), Strategic Collaboration and License Agreement (Entrada Therapeutics, Inc.), Strategic Collaboration and License Agreement (Entrada Therapeutics, Inc.)
Royalty Term. Vertex will pay royalties to Company under this Section 6.3 5.3 on a Product-by-Product and a country-by-country basis during the Royalty Term for the applicable Product in the applicable countryTerm. Upon the expiration of the Royalty Term for a given Product in a given country, the license granted to Vertex under Section 5.1.1 4.1.1 will become fully-paid, perpetual and irrevocable with respect to such Product in such countryProduct.
Appears in 2 contracts
Sources: Strategic Collaboration and License Agreement (Affinia Therapeutics Inc.), Strategic Collaboration and License Agreement (Affinia Therapeutics Inc.)
Royalty Term. Vertex ▇▇▇▇▇ will pay royalties to Company Vertex under this Section 6.3 4.3 on a Product-by-Product and a country-by-country basis during the Royalty Term for the applicable Product in the applicable countryTerm. Upon the expiration of the Royalty Term for with respect to a given Product in a given country, the license licenses granted to Vertex ▇▇▇▇▇ under Section 5.1.1 2.3 will become fully-paid, be fully paid perpetual and irrevocable with respect to such Product in such country.
Appears in 2 contracts
Sources: Assignment and License Agreement (Spero Therapeutics, Inc.), Assignment and License Agreement (Spero Therapeutics, Inc.)
Royalty Term. Vertex will pay royalties to Company under this Section 6.3 7.6 on a Licensed Product-by-Licensed Product and a country-by-country basis during the Royalty Term for the applicable such Licensed Product in the applicable such country. Upon the expiration of the Royalty Term for a given Licensed Product in a given country, the license Exclusive License granted to Vertex under Section 5.1.1 5.1 will become fully-paid, perpetual perpetual, irrevocable and irrevocable royalty-free with respect to such Licensed Product in such country.
Appears in 1 contract
Sources: Master Collaboration Agreement (Molecular Templates, Inc.)
Royalty Term. Vertex will pay royalties to Company under this Section 6.3 7.6 on a Licensed Product-by-Licensed Product and a country-by-country basis during the Royalty Term for the applicable such Licensed Product in the applicable such country. Upon the expiration of the Royalty Term for a given Licensed Product in a given country, the license Exclusive License granted to Vertex under Section 5.1.1 5.1 will become fully-paid, perpetual perpetual, irrevocable and irrevocable royalty free with respect to such Product in such countryLicensed Product.
Appears in 1 contract
Sources: Master Collaboration Agreement (Kymera Therapeutics, Inc.)
Royalty Term. Vertex will pay royalties to Company under this Section 6.3 5.5 on a Royalty Product-by-Royalty Product and a country-by-country basis during the Royalty Term for the applicable Product in the applicable country. Upon the expiration of the Royalty Term for a given Royalty Product in a given country, the license granted to Vertex under Section 5.1.1 4.1.1
(a) will become fully-paid, perpetual and irrevocable with respect to such Royalty Product in such country.
Appears in 1 contract
Sources: Strategic Collaboration and License Agreement (Verve Therapeutics, Inc.)